Financial Toxicity and Satisfaction With Cancer Treatment Among Patients With Multiple Myeloma: An Analysis of the MMRF’s CureCloud Initiative
Clinical Lymphoma Myeloma and Leukemia · 2026-02 · 26 (2) · e254-e260
DOI: 10.1016/j.clml.2025.10.007 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-02. Verfasst von Mark A Fiala und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Washington University School of Medicine, St. Louis, MO. Electronic address: mfiala@wustl.edu. Hauptthemen laut MEDLINE: Multiple Myeloma, Patient Satisfaction. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: This study explored financial toxicity and its association with treatment satisfaction among a longitudinal cohort of patients with multiple myeloma (MM). PATIENTS AND METHODS: The multiple myeloma research foundation (MMRF) CureCloud initiative (NCT03657251) is an observational study which collects biospecimens, clinical data, and patient reported outcomes (PROs). Participants completed the Comprehensive Score for Financial Toxicity (COST) and the Cancer Therapy Satisfaction Questionnaire (CTSQ). RESULTS: At the initial time point, 214 participants completed the PROs. The mean age was 68, 60% were male, and 94% were white. The median time from MM diagnosis to the baseline survey completion was 6 years. The mean COST score was 29 (SD=10) and 37% of the patients were considered to be experiencing financial toxicity. Younger patients (P < .01) and those residing in areas with lower median household incomes (P = .01) were more likely to be experiencing financial toxicity. Participants experiencing financial toxicity reported lower satisfaction with their therapy, with a mean CTSQ score 6.7 points lower than those without (P < .01). A subset of patients (n = 75) completed a second COST survey approximately 1 year later. Financial toxicity status was relatively stable; 67% (18/27) of patients experiencing it at baseline were still at the later time point and only 10% (5/48) of patients previously not experiencing financial toxicity were at the later time point. CONCLUSION: Over one-third of patients with MM were considered to be experiencing financial toxicity and financial toxicity was associated with reduced satisfaction with MM treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Oncology, Washington University School of Medicine, St. Louis, MO. Electronic address: mfiala@wustl.edu.
- Multiple Myeloma Research Foundation, Norwalk, CT.
Zitieren
APA
Fiala, M. A., Lepisto, E., Amadi-Mgbenka, C., Schulman, J., Mulligan, G., & Cho, H. J. (2026). Financial Toxicity and Satisfaction With Cancer Treatment Among Patients With Multiple Myeloma: An Analysis of the MMRF’s CureCloud Initiative. Clinical Lymphoma Myeloma and Leukemia, 26(2), e254-e260. https://doi.org/10.1016/j.clml.2025.10.007
Vancouver
Fiala MA, Lepisto E, Amadi-Mgbenka C, Schulman J, Mulligan G, Cho HJ. Financial Toxicity and Satisfaction With Cancer Treatment Among Patients With Multiple Myeloma: An Analysis of the MMRF’s CureCloud Initiative. Clinical Lymphoma Myeloma and Leukemia. 2026;26(2):e254-e260. doi:10.1016/j.clml.2025.10.007
BibTeX
@article{Fiala2026,
author = {Fiala, Mark A and Lepisto, Eva and Amadi-Mgbenka, Chioma and Schulman, Jessica and Mulligan, George and Cho, Hearn Jay},
title = {Financial Toxicity and Satisfaction With Cancer Treatment Among Patients With Multiple Myeloma: An Analysis of the MMRF’s CureCloud Initiative},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
volume = {26},
number = {2},
pages = {e254--e260},
doi = {10.1016/j.clml.2025.10.007}
}
EUVIMED